Efficacy of lurasidone across five symptom dimensions of schizophrenia: Pooled analysis of short-term, placebo-controlled studies

European Psychiatry

Volumn 30, Issue 1, 2015, Pages 26-31

  Loebel, A ^a   Cucchiaro, J ^a   Silva, R ^a   Mao, Y ^a   Xu, J ^a   Pikalov, A ^a   Marder, S R ^b  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atypical antipsychotic; Factor analysis; Lurasidone; Schizophrenia

Indexed keywords

LURASIDONE; PLACEBO; NEUROLEPTIC AGENT;

ADULT; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; EVALUATION STUDY; EXCITEMENT; FEMALE; HOSTILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE; THINKING IMPAIRMENT; META ANALYSIS; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LURASIDONE HYDROCHLORIDE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 84921057771     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2014.08.001     Document Type: Article

References (65)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, Washington, DC.
2. Amore M., Menchetti M., Tonti C., Scarlatti F., Lundgren E., Esposito W., et al. Predictors of violent behavior among acute psychiatric patients: clinical study. Psychiatry Clin Neurosci 2008, 62:247-255.
3. Andreasen N.C., Olsen S. Negative vs. positive schizophrenia. Definition and validation. Arch Gen Psychiatry 1982, 39:789-794.
4. Arndt S., Andreasen N.C., Flaum M., Miller D., Nopoulos P. A longitudinal study of symptom dimensions in schizophrenia. Prediction and patterns of change. Arch Gen Psychiatry 1995, 52:352-360.
5. Bell M.D., Lysaker P.H. Psychiatric symptoms and work performance among persons with severe mental illness. Psychiatr Serv 1995, 46:508-510.
6. Bowie C.R., Reichenberg A., Patterson T.L., Heaton R.K., Harvey P.D. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry 2006, 163:418-425.
7. Buckley P.F., Miller B.J., Lehrer D.S., Castle D.J. Psychiatric comorbidities and schizophrenia. Schizophr Bull 2009, 35:383-402.
8. Citrome L., Meng X., Hochfeld M. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. Schizophr Res 2011, 131:75-81.
9. Conley R.R., Ascher-Svanum H., Zhu B., Faries D.E., Kinon B.J. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res 2007, 90:186-197.
10. Crow T.J. Molecular pathology of schizophrenia: more than one disease process?. Br Med J 1980, 280:66-68.
11. Davis J.M., Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry 2001, 62:757-771.
12. Erickson M., Jaafari N., Lysaker P. Insight and negative symptoms as predictors of functioning in a work setting in patients with schizophrenia. Psychiatry Res 2011, 189:161-165.
13. Guy W., US Department of Health, Education, Welfare Public Health Services Alcohol Drug Abuse, Mental Health Administration ECDEU assessment manual for psychopharmacology revised, 1976 1976, 76-338. National Institute of Mental Health, Rockville, MD, [ADM].
14. Harvey P.D., Heaton R.K., Carpenter W.T., Green M.F., Gold J.M., Schoenbaum M. Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation. Schizophr Res 2012, 140:1-8.
15. Harvey P.D., Ogasa M., Cucchiaro J., Loebel A., Keefe R.S. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res 2011, 127:188-194.
16. Harvey P.D., Siu C.O., Hsu J., Cucchiaro J., Maruff P., Loebel A. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol 2013, 23:1373-1382.
17. Horacek J., Bubenikova-Valesova V., Kopecek M., Palenicek T., Dockery C., Mohr P., et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006, 20:389-409.
18. Ishibashi T., Horisawa T., Tokuda K., Ishiyama T., Ogasa M., Tagashira R., et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010, 334:171-181.
19. Janicak P.G., Glick I.D., Marder S.R., Crandall D.T., McQuade R.D., Marcus R.N., et al. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. J Clin Psychiatry 2009, 70:25-35.
20. Jerrell J.M., Hrisko S. A comparison of the PANSS pentagonal and Van Der Gaag 5-factor models for assessing change over time. Psychiatry Res 2013, 207:134-139.
21. Jin H., Zisook S., Palmer B.W., Patterson T.L., Heaton R.K., Jeste D.V. Association of depressive symptoms with worse functioning in schizophrenia: a study in older outpatients. J Clin Psychiatry 2001, 62:797-803.
22. Kane J.M., Cohen M., Zhao J., Alphs L., Panagides J. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 2010, 30:106-115.
23. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000, 157:514-520.
24. Kasper S. Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms. Eur Neuropsychopharmacol 2006, 16:S135-S141.
25. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
26. Kessler R.C., Birnbaum H., Demler O., Falloon I.R., Gagnon E., Guyer M., et al. The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry 2005, 58:668-676.
27. Kim J.H., Kim S.Y., Lee J., Oh K.J., Kim Y.B., Cho Z.H. Evaluation of the factor structure of symptoms in patients with schizophrenia. Psychiatry Res 2012, 197:285-289.
28. Lancon C., Auquier P., Nayt G., Reine G. Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS). Schizophr Res 2000, 42:231-239.
29. Leucht S., Komossa K., Rummel-Kluge C., Corves C., Hunger H., Schmid F., et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009, 166:152-163.
30. Lindenmayer J.P., Bernstein-Hyman R., Grochowski S. A new five factor model of schizophrenia. Psychiatr Q 1994, 65:299-322.
31. Lindenmayer J.P., Bernstein-Hyman R., Grochowski S., Bark N. Psychopathology of schizophrenia: initial validation of a 5-factor model. Psychopathology 1995, 28:22-31.
32. Lindenmayer J.P., Czobor P., Volavka J., Lieberman J.A., Citrome L., Sheitman B., et al. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry 2004, 65:551-556.
33. Llorca P.M., Blanc O., Samalin L., Bosia M., Cavallaro R. Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling. Eur Psychiatry 2012, 27:396-400.
34. Loebel A., Cucchiaro J., Sarma K., Xu L., Hsu C., Kalali A.H., et al. Efficacy and safety of lurasidone 80mg/day and 160mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res 2013, 145:101-109.
35. Loebel A., Cucchiaro J., Silva R., Kroger H., Hsu J., Sarma K., et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014, 171:160-168.
36. Loebel A., Cucchiaro J., Silva R., Kroger H., Xu J., Calabrese J.R. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014, 171:169-177.
37. Marder S.R., Davis J.M., Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997, 58:538-546.
38. Meltzer H.Y., Cucchiaro J., Silva R., Ogasa M., Phillips D., Xu J., et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry 2011, 168:957-967.
39. Nakamura M., Ogasa M., Guarino J., Phillips D., Severs J., Cucchiaro J., et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2009, 70:829-836.
40. Nakaya M., Suwa H., Ohmori K. Latent structures underlying schizophrenic symptoms: a five-dimensional model. Schizophr Res 1999, 39:39-50.
41. Nasrallah H.A., Cucchiaro J.B., Mao Y., Pikalov A.A., Loebel A.D. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS Spectr 2014, 23:1-8.
42. Nasrallah H.A., Silva R., Phillips D., Cucchiaro J., Hsu J., Xu J., et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res 2013, 47:670-677.
43. Nolan K.A., Volavka J., Czobor P., Sheitman B., Lindenmayer J.P., Citrome L.L., et al. Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. J Psychiatr Res 2005, 39:109-115.
44. Ogasa M., Kimura T., Nakamura M., Guarino J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl) 2013, 225:519-530.
45. Overall J.E., Gorha D.R. The brief psychiatric rating scale. Psychol Rep 1962, 799-812.
46. Pandina G., Bilder R., Turkoz I., Alphs L. Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder. Schizophr Res 2013, 143:312-318.
47. Peralta V., Cuesta M.J. How many and which are the psychopathological dimensions in schizophrenia? Issues influencing their ascertainment. Schizophr Res 2001, 49:269-285.
48. Potkin S.G., Keator D.B., Kesler-West M.L., Nguyen D.D., van Erp T.G., Mukherjee J., et al. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. CNS Spectr 2014, 19:176-181.
49. Potkin S.G., Phiri P., Szegedi A., Zhao J., Alphs L., Cazorla P. Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis. Schizophr Res 2013, 150:442-449.
50. Rabinowitz J., Levine S.Z., Garibaldi G., Bugarski-Kirola D., Berardo C.G., Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res 2012, 137:147-150.
51. Reine G., Lançon C., Di Tucci S., Sapin C., Auquier P. Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatr Scand 2003, 108:297-303.
52. Sands J.R., Harrow M. Depression during the longitudinal course of schizophrenia. Schizophr Bull 1999, 25:157-171.
53. Schwartz R.C., Cohen B.N. Psychosocial correlates of suicidal intent among patients with schizophrenia. Compr Psychiatry 2001, 42:118-123.
54. Siris S.G. Depression in schizophrenia: perspective in the era of "atypical" antipsychotic agents. Am J Psychiatry 2000, 157:1379-1389.
55. Siris S.G. Suicide and schizophrenia. J Psychopharmacol 2001, 15:127-135.
56. Soyka M., Graz C., Bottlender R., Dirschedl P., Schoech H. Clinical correlates of later violence and criminal offences in schizophrenia. Schizophr Res 2007, 94:89-98.
57. Swanson J.W., Swartz M.S., Van Dorn R.A., Elbogen E.B., Wagner H.R., Rosenheck R.A., et al. A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry 2006, 63:490-499.
58. van der Gaag M., Hoffman T., Remijsen M., Hijman R., de H.L., van M.B., et al. The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophr Res 2006, 85:280-287.
59. Velligan D.I., Alphs L., Lancaster S., Morlock R., Mintz J. Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia. Psychiatry Res 2009, 169:97-100.
60. Ventura J., Hellemann G.S., Thames A.D., Koellner V., Nuechterlein K.H. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr Res 2009, 113:189-199.
61. Vos T., Flaxman A.D., Naghavi M., Lozano R., Michaud C., Ezzati M., et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2163-2196.
62. Wallwork R.S., Fortgang R., Hashimoto R., Weinberger D.R., Dickinson D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res 2012, 137:246-250.
63. Wiersma D., Wanderling J., Dragomirecka E., Ganev K., Harrison G., an der H.W., et al. Social disability in schizophrenia: its development and prediction over 15years in incidence cohorts in six European centres. Psychol Med 2000, 30:1155-1167.
64. Wong D.F., Kuwabara H., Brasic J.R., Stock T., Maini A., Gean E.G., et al. Determination of dopamine D receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacology (Berl) 2013, 229:245-252.
65. World Health, Organization The global burden of disease: 2004 update 2008, World Health Organization, Geneva, Switzerland, [Accessed February 14, 2013]. http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf.